TY - JOUR
T1 - Design of new anticancer therapies targeting cell cycle checkpoint pathways
AU - Sampath, Deepa
AU - Plunkett, William
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 2001
Y1 - 2001
N2 - The mammalian cell cycle is exquisitely controlled by the cyclin-dependent kinases, which regulate cell cycle progression. Cell cycle transitions are, in turn, controlled by checkpoints that monitor the integrity and replication status of the genetic material before cells commit to either replicate or segregate their DNA. On activation, checkpoints interface with cyclin-Cdk complexes to block the cell cycle. Pharmacologic compounds that exploit our current knowledge of cell cycle and checkpoint pathway regulation offer insights into the development of novel therapeutic strategies.
AB - The mammalian cell cycle is exquisitely controlled by the cyclin-dependent kinases, which regulate cell cycle progression. Cell cycle transitions are, in turn, controlled by checkpoints that monitor the integrity and replication status of the genetic material before cells commit to either replicate or segregate their DNA. On activation, checkpoints interface with cyclin-Cdk complexes to block the cell cycle. Pharmacologic compounds that exploit our current knowledge of cell cycle and checkpoint pathway regulation offer insights into the development of novel therapeutic strategies.
UR - http://www.scopus.com/inward/record.url?scp=0034754073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034754073&partnerID=8YFLogxK
U2 - 10.1097/00001622-200111000-00011
DO - 10.1097/00001622-200111000-00011
M3 - Review article
C2 - 11673689
AN - SCOPUS:0034754073
SN - 1040-8746
VL - 13
SP - 484
EP - 490
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 6
ER -